Moderna Stock News
$25.13
1.67%
Nasdaq,
Apr 21, 10:18 pm CET
Moderna Stock News
Neutral
CNBC
●
20 days ago
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Negative
Investopedia
●
21 days ago
Major U.S. equities indexes were mixed to kick off the new trading week as U.S. trade policy remained in focus.
Negative
Fast Company
●
21 days ago
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization.
Negative
Invezz
●
21 days ago
Biotech investors are grappling with fresh uncertainty following the abrupt resignation of Dr. Peter Marks, a key figure in the US Food and Drug Administration.
Negative
The Motley Fool
●
21 days ago
Shares of Moderna (MRNA -9.35%) are falling on Monday. The company's stock lost 7.9% as of 1:30 p.m.
Negative
CNBC
●
21 days ago
Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Human Services Secretary Robert F.
Negative
Investors Business Daily
●
21 days ago
Biotech stocks were hammered Monday after Peter Marks, a top FDA official, resigned amid a clash with Robert F. Kennedy Jr. The post Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns appeared first on Investor's Business Daily.
Negative
Reuters
●
22 days ago
Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned, fanning worries over slower reviews for breakthrough treatments.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
